tetano
Editor, Senior Moderator
Infection
. 2021 Jan 2.
doi: 10.1007/s15010-020-01564-8. Online ahead of print.
HIV and SARS-CoV-2 co-infection: cross-sectional findings from a German 'hotspot'
S Noe[SUP] 1 [/SUP], F Schabaz[SUP] 2 [/SUP], S Heldwein[SUP] 2 [/SUP], W Mayer[SUP] 3 [/SUP], K Ruecker[SUP] 2 [/SUP], F W Tiller[SUP] 2 3 [/SUP], A von Krosigk[SUP] 2 [/SUP], C Wiese[SUP] 2 [/SUP], A Balogh[SUP] 4 [/SUP], E Gersbacher[SUP] 4 [/SUP], C Jonsson-Oldenbuettel[SUP] 2 [/SUP], H Jaeger[SUP] 2 [/SUP], E Wolf[SUP] 4 [/SUP], ArcHIV study group.
Affiliations
Abstract
Purpose: This study aimed to determine the proportion of people living with HIV with anti-SARS-CoV-2 IgG antibodies in a sample from a large single HIV center in Munich, Germany, after the first phase of the coronavirus pandemic and to infer the prevalence of SARS-CoV-2 co-infection in people living with HIV.
Methods: Prospective sub-study of the ongoing ArcHIV cohort between May and July 2020. Anti-SARS-CoV-2 IgG antibodies were measured using the recomWell SARS-CoV-2 IgG ELISA (Mikrogen, Neuried, Germany); positive and borderline results were re-tested using the recomLine SARS-CoV-2 IgG immunoassay (Mikrogen, Neuried, Germany). Demographic and medical data were extracted from the electronic patient files.
Results: Overall, 500 people living with HIV were included in the study (83% male, median age 51 years). Three participants had been diagnosed with COVID-19 prior to study inclusion. Of those, nine were confirmed positive for SARS-CoV-2 IgG antibodies, resulting in an estimated seroprevalence (accounting for sensitivity and specificity of the test) of 1.5% (CI 95%: 0.69; 3.13) for the entire study sample, and 2.2% (CI 95%: 1.1; 3.9) for the subset of the Munich citizens. There were no marked differences for people living with HIV with and without SARS-CoV-2 co-infection.
Conclusion: The seroprevalence of SARS-CoV-2 co-infection in people living with HIV as found in our study does not seem to exceed previous reports from general populations of 'hot-sport' areas; comparative data from the Munich population can be expected to be published soon. Our data also highlight, once more, the need to do confirmatory testing on positive samples to minimize the impact of false-positive results.
Keywords: Antiretroviral therapy; COVID-19; Munich.
. 2021 Jan 2.
doi: 10.1007/s15010-020-01564-8. Online ahead of print.
HIV and SARS-CoV-2 co-infection: cross-sectional findings from a German 'hotspot'
S Noe[SUP] 1 [/SUP], F Schabaz[SUP] 2 [/SUP], S Heldwein[SUP] 2 [/SUP], W Mayer[SUP] 3 [/SUP], K Ruecker[SUP] 2 [/SUP], F W Tiller[SUP] 2 3 [/SUP], A von Krosigk[SUP] 2 [/SUP], C Wiese[SUP] 2 [/SUP], A Balogh[SUP] 4 [/SUP], E Gersbacher[SUP] 4 [/SUP], C Jonsson-Oldenbuettel[SUP] 2 [/SUP], H Jaeger[SUP] 2 [/SUP], E Wolf[SUP] 4 [/SUP], ArcHIV study group.
Affiliations
- PMID: 33387261
- DOI: 10.1007/s15010-020-01564-8
Abstract
Purpose: This study aimed to determine the proportion of people living with HIV with anti-SARS-CoV-2 IgG antibodies in a sample from a large single HIV center in Munich, Germany, after the first phase of the coronavirus pandemic and to infer the prevalence of SARS-CoV-2 co-infection in people living with HIV.
Methods: Prospective sub-study of the ongoing ArcHIV cohort between May and July 2020. Anti-SARS-CoV-2 IgG antibodies were measured using the recomWell SARS-CoV-2 IgG ELISA (Mikrogen, Neuried, Germany); positive and borderline results were re-tested using the recomLine SARS-CoV-2 IgG immunoassay (Mikrogen, Neuried, Germany). Demographic and medical data were extracted from the electronic patient files.
Results: Overall, 500 people living with HIV were included in the study (83% male, median age 51 years). Three participants had been diagnosed with COVID-19 prior to study inclusion. Of those, nine were confirmed positive for SARS-CoV-2 IgG antibodies, resulting in an estimated seroprevalence (accounting for sensitivity and specificity of the test) of 1.5% (CI 95%: 0.69; 3.13) for the entire study sample, and 2.2% (CI 95%: 1.1; 3.9) for the subset of the Munich citizens. There were no marked differences for people living with HIV with and without SARS-CoV-2 co-infection.
Conclusion: The seroprevalence of SARS-CoV-2 co-infection in people living with HIV as found in our study does not seem to exceed previous reports from general populations of 'hot-sport' areas; comparative data from the Munich population can be expected to be published soon. Our data also highlight, once more, the need to do confirmatory testing on positive samples to minimize the impact of false-positive results.
Keywords: Antiretroviral therapy; COVID-19; Munich.